Latest Regeneron Pharmaceuticals (REGN) Headlines
Uptrend Call Working As Regeneron Pharmaceuticals Stock Rises 19.1% (REGN)
Comtex SmarTrend(R) - 2 hrs 39 mins ago
SmarTrend identified an Uptrend for Regeneron Pharmaceuticals (NASDAQ:REGN) on January 14th, 2014 at $284.86. In approximately 2 months, Regeneron Pharmaceuticals has returned 19.08% as of today's recent price of $339.21.
Better Biotech Buy: Alexion Pharmaceuticals, Inc. vs. Regeneron
Dan Carroll, The Motley Fool - Motley Fool - Wed Mar 12, 1:30PM CDT
Big biotech stocks like Alexion Pharmaceuticals and Regeneron have soared through the market's recent rally with flying colors. These two stocks alone each have captured more than 90% growth over that time, as climbing sales of top drugs have...
Biotech Stock Roundup: Amgen, Regeneron Slide on PCSK9 Inhibitor Concerns - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Mar 12, 9:50AM CDT
Last week's highlights include safety concerns regarding a new class of drugs and takeover rumors.
Marketing Authorization Applications, Quarterly Dividends, Publication of Clinical Trial Data, Acquisitions, and Financial Results - Analyst Notes on Regeneron, Amgen, Sangamo, Alnylam, and Agios
PR Newswire - Tue Mar 11, 8:08AM CDT
Today, Analysts Review released its analysts' notes regarding Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), Amgen, Inc. (NASDAQ: AMGN), Sangamo BioSciences, Inc. (NASDAQ: SGMO), Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), and Agios Pharmaceuticals, Inc. (NASDAQ: AGIO). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Who Will Capture This $3.5 Billion Opportunity?
Todd Campbell, The Motley Fool - Motley Fool - Mon Mar 10, 5:30PM CDT
Two of the most highly successful compounds to win FDA approval in the past few years have been Regeneron's Eylea and Novartis ' and Roche 's Lucentis. Both drugs help improve vision in patients who are losing their sight due to age or...
FDA Cholesterol Drug Concerns: What You Should Know
Stephen D., Simpson,, The Motley Fool - Motley Fool - Mon Mar 10, 1:30PM CDT
As Sanofi / Regeneron , Pfizer , and Amgen prepare for the stretch run to getting their PCSK9 inhibitors, high-potential new treatments for cholesterol, approved by the FDA, a new potential complication has emerged. Sanofi and Regeneron...
The Most Amazing S&P Stocks of the Past 7 Years
Dan Caplinger, The Motley Fool - Motley Fool - Sat Mar 08, 10:30AM CST
Five years ago, the stock market hit its lowest levels of the 2008 and 2009 bear market, and since then, the S&P 500 has soared more than 1,200 points. But rather than focusing only on the performance of stocks since the worst of times during...
Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan
at The Street - Fri Mar 07, 7:17PM CST
Cramer will be watching a number of conferences for a read on the economy.
Surprise FDA Red Flags May Jeopardize Blockbuster Drugs
David Williamson, The Motley Fool - Motley Fool - Fri Mar 07, 6:57PM CST
Regeneron is today's big loser in the biotech space because of a new set of FDA concerns over its PCSK9 drug. The FDA is now concerned that this class of drugs, aimed at lowering "bad" cholesterol in the bloodstream, could have a number of...
The Biggest Winners Since the Bull Market Began
Dan Caplinger, The Motley Fool - Motley Fool - Fri Mar 07, 6:03PM CST
On March 9, 2009, stocks hit what would turn out to be their lowest levels of the bear market of 2008 and early 2009. In the five years since then, investors have seen huge gains in the stock market, with even the major-market benchmarks posting...
Regeneron falls on FDA probe
at Investor's Business Daily - Fri Mar 07, 5:52PM CST
Shares of the drugmaker, whose Eylea treatment for wet age-related macular degeneration is a top seller, plunged 10% Fri. after trading was briefly halted for volatility, after word got out that the FDA is investigating its cholesterol-drug candidate...
Look for Shares of Regeneron Pharmaceuticals to Potentially Rebound after Yesterday's 3.06% Sell Off
Comtex SmarTrend(R) - Fri Mar 07, 3:41PM CST
Regeneron Pharmaceuticals (NASDAQ:REGN) traded in a range yesterday that spanned from a low of $304.20 to a high of $343.50. Yesterday, the shares fell 3.1%, which took the trading range below the 3-day low of $338.01 on volume of 4.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Nasdaq Lags As Stock Market Closes Lower
at Investor's Business Daily - Fri Mar 07, 3:28PM CST
Stocks closed mixed as a better-than-expected jobs report failed to hold the market's interest. Indexes opened higher after the Labor Department reported an increase of 175,000 jobs in February, while the unemployment rate edged up to 6.7%. But the...
Early Gains Fade; E-House Breaks Out But Biotechs Stumble
at Investor's Business Daily - Fri Mar 07, 2:33PM CST
Enthusiasm was short-lived in the stock market after Friday's better-than-expected jobs report. All three major averages were near session lows after early strength. With a little over one hour remaining in the session, selling was most pronounced in...
Nike's Bounce Can't Stop the Dow's Slip
Dan Carroll, The Motley Fool - Motley Fool - Fri Mar 07, 1:36PM CST
Stocks have slipped from earlier gains on the day, with the Dow Jones Industrial Average down nearly five points as of 2:30 and eying a downbeat ending for the week. The blue-chip index's stocks are split fairly evenly between risers and laggards,...
Regeneron Cholesterol-Drug Worries Ding Stock
at Investor's Business Daily - Fri Mar 07, 1:11PM CST
Regeneron Pharmaceuticals (REGN) plunged 10% Friday afternoon after trading was briefly halted for volatility, after word got out that the FDA is investigating its cholesterol-drug candidate for adverse effects. The item was buried deep in a 20-F...
Water-Logged And Getting Wetter: Regeneron Pharmaceuticals (REGN)
at The Street - Fri Mar 07, 12:17PM CST
Trade-Ideas LLC identified Regeneron Pharmaceuticals (REGN) as a "water-logged and getting wetter" (weak stocks crossing below support with today's range greater than 200%) candidate
Stock Price Updates, Appointment, and Financial Results - Analyst Notes on Regeneron, DENTSPLY, AMAG, Cadence, and ArthroCare
PR Newswire - Thu Mar 06, 10:50AM CST
Today, Analysts Review released its analysts' notes regarding Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), DENTSPLY International Inc. (NASDAQ: XRAY), AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG), Cadence Pharmaceuticals Inc. (NASDAQ: CADX), and ArthroCare Corporation (NASDAQ: ARTC). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Insider Trading Alert - CNW, PPS And REGN Traded By Insiders
at The Street - Thu Mar 06, 10:45AM CST
Stocks with insider trader activity include CNW, PPS and REGN
Uptrend Call Working As Regeneron Pharmaceuticals Stock Rises 21.3% (REGN)
Comtex SmarTrend(R) - Wed Mar 05, 5:15PM CST
SmarTrend identified an Uptrend for Regeneron Pharmaceuticals (NASDAQ:REGN) on January 14th, 2014 at $284.86. In approximately 2 months, Regeneron Pharmaceuticals has returned 21.28% as of today's recent price of $345.49.
Uptrend Call Working As Regeneron Pharmaceuticals Stock Rises 19.1% (REGN)
Comtex SmarTrend(R) - 2 hrs 39 mins ago
SmarTrend identified an Uptrend for Regeneron Pharmaceuticals (NASDAQ:REGN) on January 14th, 2014 at $284.86. In approximately 2 months, Regeneron Pharmaceuticals has returned 19.08% as of today's recent price of $339.21.
Better Biotech Buy: Alexion Pharmaceuticals, Inc. vs. Regeneron
Dan Carroll, The Motley Fool - Motley Fool - Wed Mar 12, 1:30PM CDT
Big biotech stocks like Alexion Pharmaceuticals and Regeneron have soared through the market's recent rally with flying colors. These two stocks alone each have captured more than 90% growth over that time, as climbing sales of top drugs have...
Biotech Stock Roundup: Amgen, Regeneron Slide on PCSK9 Inhibitor Concerns - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Mar 12, 9:50AM CDT
Last week's highlights include safety concerns regarding a new class of drugs and takeover rumors.
Marketing Authorization Applications, Quarterly Dividends, Publication of Clinical Trial Data, Acquisitions, and Financial Results - Analyst Notes on Regeneron, Amgen, Sangamo, Alnylam, and Agios
PR Newswire - Tue Mar 11, 8:08AM CDT
Today, Analysts Review released its analysts' notes regarding Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), Amgen, Inc. (NASDAQ: AMGN), Sangamo BioSciences, Inc. (NASDAQ: SGMO), Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), and Agios Pharmaceuticals, Inc. (NASDAQ: AGIO). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Who Will Capture This $3.5 Billion Opportunity?
Todd Campbell, The Motley Fool - Motley Fool - Mon Mar 10, 5:30PM CDT
Two of the most highly successful compounds to win FDA approval in the past few years have been Regeneron's Eylea and Novartis ' and Roche 's Lucentis. Both drugs help improve vision in patients who are losing their sight due to age or...
FDA Cholesterol Drug Concerns: What You Should Know
Stephen D., Simpson,, The Motley Fool - Motley Fool - Mon Mar 10, 1:30PM CDT
As Sanofi / Regeneron , Pfizer , and Amgen prepare for the stretch run to getting their PCSK9 inhibitors, high-potential new treatments for cholesterol, approved by the FDA, a new potential complication has emerged. Sanofi and Regeneron...
The Most Amazing S&P Stocks of the Past 7 Years
Dan Caplinger, The Motley Fool - Motley Fool - Sat Mar 08, 10:30AM CST
Five years ago, the stock market hit its lowest levels of the 2008 and 2009 bear market, and since then, the S&P 500 has soared more than 1,200 points. But rather than focusing only on the performance of stocks since the worst of times during...
Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan
at The Street - Fri Mar 07, 7:17PM CST
Cramer will be watching a number of conferences for a read on the economy.
Surprise FDA Red Flags May Jeopardize Blockbuster Drugs
David Williamson, The Motley Fool - Motley Fool - Fri Mar 07, 6:57PM CST
Regeneron is today's big loser in the biotech space because of a new set of FDA concerns over its PCSK9 drug. The FDA is now concerned that this class of drugs, aimed at lowering "bad" cholesterol in the bloodstream, could have a number of...
The Biggest Winners Since the Bull Market Began
Dan Caplinger, The Motley Fool - Motley Fool - Fri Mar 07, 6:03PM CST
On March 9, 2009, stocks hit what would turn out to be their lowest levels of the bear market of 2008 and early 2009. In the five years since then, investors have seen huge gains in the stock market, with even the major-market benchmarks posting...
Regeneron falls on FDA probe
at Investor's Business Daily - Fri Mar 07, 5:52PM CST
Shares of the drugmaker, whose Eylea treatment for wet age-related macular degeneration is a top seller, plunged 10% Fri. after trading was briefly halted for volatility, after word got out that the FDA is investigating its cholesterol-drug candidate...
Look for Shares of Regeneron Pharmaceuticals to Potentially Rebound after Yesterday's 3.06% Sell Off
Comtex SmarTrend(R) - Fri Mar 07, 3:41PM CST
Regeneron Pharmaceuticals (NASDAQ:REGN) traded in a range yesterday that spanned from a low of $304.20 to a high of $343.50. Yesterday, the shares fell 3.1%, which took the trading range below the 3-day low of $338.01 on volume of 4.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Nasdaq Lags As Stock Market Closes Lower
at Investor's Business Daily - Fri Mar 07, 3:28PM CST
Stocks closed mixed as a better-than-expected jobs report failed to hold the market's interest. Indexes opened higher after the Labor Department reported an increase of 175,000 jobs in February, while the unemployment rate edged up to 6.7%. But the...
Early Gains Fade; E-House Breaks Out But Biotechs Stumble
at Investor's Business Daily - Fri Mar 07, 2:33PM CST
Enthusiasm was short-lived in the stock market after Friday's better-than-expected jobs report. All three major averages were near session lows after early strength. With a little over one hour remaining in the session, selling was most pronounced in...
Nike's Bounce Can't Stop the Dow's Slip
Dan Carroll, The Motley Fool - Motley Fool - Fri Mar 07, 1:36PM CST
Stocks have slipped from earlier gains on the day, with the Dow Jones Industrial Average down nearly five points as of 2:30 and eying a downbeat ending for the week. The blue-chip index's stocks are split fairly evenly between risers and laggards,...
Regeneron Cholesterol-Drug Worries Ding Stock
at Investor's Business Daily - Fri Mar 07, 1:11PM CST
Regeneron Pharmaceuticals (REGN) plunged 10% Friday afternoon after trading was briefly halted for volatility, after word got out that the FDA is investigating its cholesterol-drug candidate for adverse effects. The item was buried deep in a 20-F...
Water-Logged And Getting Wetter: Regeneron Pharmaceuticals (REGN)
at The Street - Fri Mar 07, 12:17PM CST
Trade-Ideas LLC identified Regeneron Pharmaceuticals (REGN) as a "water-logged and getting wetter" (weak stocks crossing below support with today's range greater than 200%) candidate
Stock Price Updates, Appointment, and Financial Results - Analyst Notes on Regeneron, DENTSPLY, AMAG, Cadence, and ArthroCare
PR Newswire - Thu Mar 06, 10:50AM CST
Today, Analysts Review released its analysts' notes regarding Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), DENTSPLY International Inc. (NASDAQ: XRAY), AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG), Cadence Pharmaceuticals Inc. (NASDAQ: CADX), and ArthroCare Corporation (NASDAQ: ARTC). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Insider Trading Alert - CNW, PPS And REGN Traded By Insiders
at The Street - Thu Mar 06, 10:45AM CST
Stocks with insider trader activity include CNW, PPS and REGN
Uptrend Call Working As Regeneron Pharmaceuticals Stock Rises 21.3% (REGN)
Comtex SmarTrend(R) - Wed Mar 05, 5:15PM CST
SmarTrend identified an Uptrend for Regeneron Pharmaceuticals (NASDAQ:REGN) on January 14th, 2014 at $284.86. In approximately 2 months, Regeneron Pharmaceuticals has returned 21.28% as of today's recent price of $345.49.
